1. Cell Cycle/DNA Damage
    Autophagy
  2. CDK
    Autophagy

Flavopiridol (Synonyms: L868275; HMR-1275; Alvocidib)

Cat. No.: HY-10005 Purity: 99.11%
Data Sheet SDS Handling Instructions

Flavopiridol is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of around 40 nM.

For research use only. We do not sell to patients.
Flavopiridol Chemical Structure

Flavopiridol Chemical Structure

CAS No. : 146426-40-6

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $195 In-stock
100 mg $360 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Flavopiridol:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Flavopiridol is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of around 40 nM.

IC50 & Target

IC50: 40 nM (CDK)

In Vitro

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00464633 Sanofi Leukemia, Lymphocytic, Chronic March 2007 Phase 2
NCT00098579 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor|Recurrent Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma October 2004 Phase 1
NCT00080990 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific February 2004 Phase 1
NCT00377104 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Small Lymphocytic Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma September 2006 Phase 1
NCT00112723 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurren December 2005 Phase 1|Phase 2
NCT00112684 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific February 2006 Phase 1
NCT00101231 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia Wit October 2004 Phase 1
NCT00058240 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Waldenström Macroglobulinemia April 2003 Phase 1|Phase 2
NCT00735930 National Cancer Institute (NCI) Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Thrombocytopenia August 2008 Phase 1
NCT00098371 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia April 2005 Phase 2
NCT00407966 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia Wit October 2006 Phase 2
NCT00324480 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific March 2006 Phase 1
NCT00278330 National Cancer Institute (NCI) Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Relapsing Chronic Myelogenous Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia January 2006 Phase 1
NCT01076556 National Cancer Institute (NCI) Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma April 2010 Phase 1
NCT00047203 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma September 2002 Phase 2
NCT00331682 National Cancer Institute (NCI) Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer March 2006 Phase 2
NCT00991952 National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer September 2009 Phase 2
NCT00003620 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia June 1999 Phase 2
NCT00047307 National Cancer Institute (NCI) Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer August 2002 Phase 1
NCT00012181 National Cancer Institute (NCI) Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Childhood S April 2001 Phase 1
NCT00957905 National Cancer Institute (NCI) Recurrent Extragonadal Seminoma|Recurrent Malignant Extragonadal Germ Cell Tumor|Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Stage III Testicular Cancer|Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Ovarian Germ Cell Tumor June 2009 Phase 2
NCT00079352 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific April 2004 Phase 1
NCT01349972 National Cancer Institute (NCI) Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute M April 2011 Phase 2
NCT00058227 National Cancer Institute (NCI) B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage I April 2003 Phase 1
NCT00072436 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2003 Phase 1
NCT00070239 National Cancer Institute (NCI) Hematopoietic/Lymphoid Cancer|Unspecified Adult Solid Tumor, Protocol Specific August 2003 Phase 1
NCT00046917 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2002 Phase 1
NCT00795002 National Cancer Institute (NCI) Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid L November 2008 Phase 2
NCT00003256 National Cancer Institute (NCI) Prostate Cancer May 1998 Phase 2
NCT00005974 NCIC Clinical Trials Group|Canadian Cancer Trials Group Sarcoma July 2000 Phase 2
NCT00039455 National Cancer Institute (NCI) HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer April 2002 Phase 1
NCT00082784 National Cancer Institute (NCI) Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglo March 2004 Phase 1
NCT00003039 National Cancer Institute (NCI) Lymphoma September 1997 Phase 2
NCT00083122 National Cancer Institute (NCI) Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Primary Peritoneal Cavity Cancer April 2004 Phase 2
NCT00019344 National Cancer Institute (NCI) Lymphoma|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific August 1997 Phase 1
NCT00005971 NCIC Clinical Trials Group|Canadian Cancer Trials Group Melanoma (Skin) July 2000 Phase 2
NCT00016939 Southwest Oncology Group|National Cancer Institute (NCI) Kidney Cancer May 2001 Phase 2
NCT00023894 Gynecologic Oncology Group|National Cancer Institute (NCI) Endometrial Cancer July 2001 Phase 2
NCT00005074 NCIC Clinical Trials Group|Canadian Cancer Trials Group Lymphoma January 2000 Phase 2
NCT00007917 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific January 2001 Phase 1
NCT00064285 Virginia Commonwealth University|National Cancer Institute (NCI) Leukemia June 2003 Phase 1
NCT00016016 National Cancer Institute (NCI) Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia February 2001 Phase 1|Phase 2
NCT00016185 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific March 2001 Phase 1
NCT00470197 National Cancer Institute (NCI) Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22; April 2007 Phase 1
NCT00087282 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Liver Cancer June 2004 Phase 2
NCT00021073 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific May 2001 Phase 1
NCT00094978 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma October 25, 2004 Phase 1
NCT00006485 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2000 Phase 1
NCT00006245 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Esophageal Cancer July 2000 Phase 2
NCT02520011 Tolero Pharmaceuticals, Inc. Acute Myeloid Leukemia March 14, 2016 Phase 2
NCT00003690 Mayo Clinic|National Cancer Institute (NCI) Breast Cancer|Melanoma (Skin)|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific December 1998 Phase 1
NCT00042874 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific May 2002 Phase 1
NCT00020189 National Cancer Institute (NCI) Head and Neck Cancer|Thromboembolism June 2000 Phase 2
NCT00020332 National Cancer Institute (NCI) Breast Cancer October 2000 Phase 1|Phase 2
NCT00045448 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific April 2002 Phase 1
NCT00634244 National Cancer Institute (NCI) Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22; October 2008 Phase 2
NCT00003004 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 1997 Phase 1
NCT00445341 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma January 2007 Phase 1|Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.4886 mL 12.4428 mL 24.8855 mL
5 mM 0.4977 mL 2.4886 mL 4.9771 mL
10 mM 0.2489 mL 1.2443 mL 2.4886 mL
Kinase Assay
[1]

Briefly, lysates containing approximately 3×106 cells are incubated with 50 μM LEVD-AFC (caspase 4 substrate) or LETD-AFC (caspase 8 substrate) containing 10 mM dithiothretiol (DTT). caspase 4 activity is measured one hour after addition of substrate and caspase 8 activity is measured 30 minutes after addition of substrate. Release of free AFC is measured with a Beckman-Coulter DTX 880 multimode detector.

Cell Assay
[1]

The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/chloroquine samples, chloroquine is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously.

References
M.Wt

401.84

Formula

C₂₁H₂₀ClNO₅

CAS No.

146426-40-6

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.11%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Flavopiridol
Cat. No.:
HY-10005
Quantity: